Close Icon We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Pharma Consulting

Close Icon

Hot topics

Thought leadership

Research and development strategy

Close Icon

Events

Conferences 2020

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

Support for fast pharmaceutical regulatory approval

Our intelligence on approved and pipeline drugs, plus regulatory information on devices/diagnostics help you plan your route to commercial success.

Your window on the pipeline

To achieve commercial success, you need to connect successful approved drugs and mid-to-late stage pipeline drugs to the underlying trial information. You’ll also want to focus in on the best trial designs and comparator arms that have met with success across target markets.

What we offer

Our solutions give you the tools and intelligence to quickly build up a landscape of approved and pipeline drugs for a disease of interest. We cover where drugs have been approved or are in development, and timeline projections for clinical trials and time to regulatory approvals.
You’ll also be able to find comprehensive, accurate regulatory information on devices/diagnostics, particularly for FDA and CE Mark approvals.
Plus, you can save time filtering information by mechanism of action or drug class.

How it helps

We’ll help you:

Stay up to date with new regulatory trends/changes in pharma and medtech
Anticipate label claims of your competitors and ensure your product has a strong and promising future in the market
Learn from the pitfalls of terminated trials for similar drugs
Understand successful (and unsuccessful) strategies to achieve priority regulatory designations, that you can incorporate into your own development plans
Tap into the industry’s top analysts to help with your research needs

Relevant products

Pink Sheet: global policy and regulatory coverage

Unparalleled access to global pharma regulatory and compliance intelligence and expertise.

Key benefits:

Get a global view
Go beyond the news
Hear from news makers

HBW Insight: Health, Beauty and Wellness

The single most comprehensive consumer healthcare information source covering regulatory, legislative, legal and commercial news across the over the counter medicines, vitamins and dietary supplements, and cosmetics industries.

Key benefits:

Get a global view
Be the first to know
Go beyond the news

Biomedtracker: follow the drug development process

Track and assess key events that will impact a drug’s probability of technical success and approval.

Key benefits:

Stay up to date
Get ahead of the competition
Conference coverage

View all content

Generics Bulletin

Celltrion Makes Progress On Coronavirus Treatment

Celltrion has accelerated the development of its antiviral treatment for COVID-19 and aims to launch a rapid self-testing kit that could provide results within 15-20 minutes. The Korean firm also plans to develop a ‘super antibody’ to prepare for potential future pandemic situations.

Topic Coronavirus

View article
HBW Insight

The Race Is On To Launch COVID-19 Antibody Home-Test In The UK

Feature: Public Health England has revealed it is only a week away from approving a COVID-19 antibody test for distribution via Amazon. HBW Insight looks at the race to place the first, government-approved coronavirus home-test on the UK market.

Topic Coronavirus

View article
Biomedtracker, Trialtrove, Pharmaprojects, Scrip, Pink Sheet...

COVID-19 Infographic

Access the infographic below which explores the number of treatment drugs for COVID-19 currently in clinical trials or in development, events including progress updates, partnerships, regulatory and trial announcements etc, and the number of articles published on COVID-19 as of March 3, 2020. This data has been tracked and reported via Informa Pharma Intelligence’s clinical, regulatory and commercial data and analytics, and news and insight tools including Biomedtracker, Trialtrove, Pharmaprojects, Scrip, Pink Sheet, Medtech Insight, and Generics Bulletin etc.

Topic Coronavirus

View infographic
Biomedtracker

Biomedtracker Potential Pivots in 2020

In this infographic, we provide insight into key trials that are expecting developments in the approval process.

View infographic
Generics Bulletin

Sandoz, Teva And Mylan Step Up On Hydroxychloroquine

To meet expected demand in the weeks and months ahead, Novartis' Sandoz has committed to donate up to 130 million doses of generic hydroxychloroquine – a treatment for malaria currently under investigation as a therapy to aid in the COVID-19 pandemic – while Teva and Mylan have also made strides, as the generics industry continues to play its part in tackling the coronavirus outbreak.

Topic Coronavirus

View article
In Vivo, HBW Insight, Pink Sheet, Scrip, Generics Bulletin, ...

Coronavirus: Keep up to date with Breaking News and Insight

Track the latest developments in the worldwide coronavirus outbreak and what it means for the pharma, medtech, generics and OTC industries with coverage from the Informa Pharma Intelligence Insights suite of tools. Get vital breaking news and penetrating analysis about the impact of this global health crisis.

Topic Coronavirus

Single report
Generics Bulletin

Preserving Full Capacity Is Key To Global Coronavirus Reponse

Leaders around the world must do all they can to ensure that medicines manufacturing and the supply chain are operating at full capacity as part of efforts to tackle the coronavirus outbreak, global off-patent industry association the IGBA has urged.

Topic Coronavirus

View article
Generics Bulletin

Celltrion Pledges Efforts on Coronavirus Antibody And Kit

Celltrion unveils emergency plans to deal with the COVID-19 situation in South Korea by speeding up development of a potential therapeutic antibody and rapid, accurate testing kit without considering economic returns.

Topic Coronavirus

View article
HBW Insight

EU Coronavirus Situation 'Evolving Very Rapidly' Says AESGP

In response to the outbreak of the Covid-19 pandemic in Europe, the region's self-care industry is working hard to keep shelves stocked with crucial OTC medicines and food supplements, according to the AESGP.

Topic Coronavirus

View article
Generics Bulletin

Green Lanes Will Help EU Fight Coronavirus

Industry has welcomed the European Commission’s introduction of priority freight lanes, or ‘green lanes’, for essential goods to help address the challenges posed by the coronavirus outbreak.

Topic Coronavirus

View article
HBW Insight

Covid-19 Disrupting Supply Chains Short-Term, Could Spark Long-Term Procurement Shifts

UNPA anticipates supplies of a ‘significant number’ of China-sourced supplement ingredients will be ‘critical’ by late April as Covid-19 disrupts shipments. During a recent webinar, UNPA CEO Loren Israelsen said he expects disruptions to continue until at least mid-year.

View article
HBW Insight

Coronavirus Disruption Likely In Supply Chain, Stockpiling Spikes Consumer Health Sales

Hand sanitizer, vitamin, energy drink, first-aid kis and medical face mask sales soar globally as consumers fearing spread of the coronavirus stockpile food and other essentials, a Nielsen report shows. FDA says outbreak could lead to interruptions in drug and medical device supplies; agency has not addressed consumer health supplies specifically, and industry is increasingly concerned with availability.

Topic Coronavirus

View article
HBW Insight

Coronavirus Slams US Consumer Health Industry Event Schedules, FDA Meetings, Inspections

In addition to postponing NDAC meeting on food handler antiseptic drug products, FDA is suspending most inspections of foreign manufacturing facilities through April. Latest consumer health industry conferences cancelled or postponed are Consumer Healthcare Product Association and Informa Markets events.

Topic Coronavirus

View article
HBW Insight

Supplement Industry Summit Postponed, But Sales Jump As Consumers Respond To Covid-19

Dietary Supplements Regulatory Summit scheduled for 27 May in Washington is postponed. Even as supplies from China are slowed or interrupted due to Covid-19, though, sales of some consumer health products jump as consumers respond to the public health threat.

View article
HBW Insight

Bogus Coronavirus Claims For Silver, Essential Oils, Herbalist's Tea 'Protocol' Plus A Price Discount

Obviously unsubstantiated claims on how the products either prevent or cure the virus didn’t escape FDA and FTC's attention -- they warned seven firms attempting to capitalize on consumer fears. They warnings are the “first step” and they plan to enforce action against companies that continue to market products with treatment claims.

Topic Coronavirus

View article